An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer
Launched by JONSSON COMPREHENSIVE CANCER CENTER · Sep 23, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new type of imaging test called a PET scan, which uses a special substance known as Me-4FDG to help detect lung cancer early. The goal is to see how safely and effectively this new test can identify lung adenocarcinoma, a common type of lung cancer. By using Me-4FDG, researchers hope to find out if it can better show areas in the body where glucose (a type of sugar) is being taken up by cancer cells, compared to traditional methods.
To participate in this study, individuals must be over 18 years old and have a lung nodule that is at least 1 centimeter in size, as seen on a CT scan. There are two groups in the trial: one for those with confirmed lung cancer and another for those with nodules that are believed to be non-cancerous. Participants can expect to undergo the PET scan and possibly additional tests, depending on their situation. It’s important to note that certain individuals, such as those who are pregnant or have diabetes, are not eligible for this trial. Overall, this study aims to enhance early lung cancer detection, which could lead to better treatment outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18 years
- • Lung nodule \>= 1 cm visualized by CT imaging
- • CANCER ARM: Pathologically confirmed lung adenocarcinoma. For patients who are surgical candidates, the pathologic report on the surgical specimen will confirm the diagnosis. For patients who are not surgical candidates, the enrollment will be contingent upon a pathologic diagnosis of lung cancer obtained by needle biopsy
- • BENIGN ARM: Lung nodules considered to be clinically benign, according to the Guidelines for Management of Incidental Pulmonary Nodules from the Fleischner Society. Will consider "benign" the nodules with a lung-RADS score of 1-3
- Exclusion Criteria:
- • Pregnancy
- • Diagnosis of diabetes
- • Current treatment with SGLT2 inhibitors or metformin
About Jonsson Comprehensive Cancer Center
The Jonsson Comprehensive Cancer Center (JCCC) is a leading research and treatment institution dedicated to advancing cancer prevention, diagnosis, and treatment through innovative clinical trials and cutting-edge research. Affiliated with the University of California, Los Angeles (UCLA), the JCCC integrates a multidisciplinary approach, bringing together experts in oncology, genetics, and public health to foster collaboration and translate scientific discoveries into effective therapies. With a commitment to improving patient outcomes and quality of life, the JCCC conducts a wide range of clinical trials aimed at addressing various cancer types, ensuring that patients have access to the most advanced therapeutic options available.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Los Angeles, California, United States
Patients applied
Trial Officials
Claudio Scafoglio, MD, PhD
Principal Investigator
UCLA / Jonsson Comprehensive Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials